期刊文献+

炎症与动脉粥样硬化关系研究进展 被引量:65

The Progression of The Relation Between Inflammation and Atherosclerosis
下载PDF
导出
摘要 研究表明动脉粥样硬化是一种慢性炎症,在内皮损伤、脂质代谢异常、血流动力学损伤、遗传、感染、物理化学等损伤刺激下,多种炎症因子、免疫机制及相关细胞因子网络交叉样作用于血管壁,形成慢性炎症。炎症反应贯穿于动脉粥样硬化的启动、形成和发展以及不稳定斑块,众多的的炎症标志物为动脉粥样硬化的评估和临床预测提供一条重要途径。抗炎症治疗在动脉粥样硬化的防治中不断取得突破。 Atherosclerosis is a chronic inflammation. Under the stimulation of endothelium injury, abnormality of lipid metabolism hemodynamics injury, heredity, inflammation and physical chemistry, chronic inflammtion of blood vessel can be informed by the effects of many kinds of inflammtory factors, immunologic mechnism and cytokines. Inflammation exist in the onset, formation, development and unstable plaque Mang inflammatory marker provide one important way for the evaluation ang clinical anticipation of atherosclerosis. Antiinflammatory therapy gets constant breakthrough in the prevention and cure of the atherosclerosis.
出处 《中国分子心脏病学杂志》 CAS 2010年第3期184-188,共5页 Molecular Cardiology of China
基金 青岛市卫生局医药科研指导计划项目(2007WSZD076) 山东省优秀中青年科学家科研奖励基金(2007BS03016)
关键词 内科学 炎症 动脉粥样硬化 标志物 防治 Internal Medicine Inflammation Atherosclerosis Marker Prevention and Cure Review
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献345

同被引文献593

引证文献65

二级引证文献426

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部